Federal US prosecutors in the criminal case against Lauren Stevens, the indicted former in-house counsel of UK drug giant GlaxoSmithKline (LSE: GSK) received a double dose of bad news last week. First the judge ruled against the government in saying that Ms Stevens can claim an advice-of-counsel defense to the charges against her. Then the judge dismissed the case without prejudice.
Ms Stevens was indicted last fall on several counts. She is accused of trying to obstruct the FDA's probe into whether GSK had off-label marketed the depression drug Wellbutrin SR (bupropion; The Pharma Letter November 10, 2010).
Judge Roger Titus found that the prosecutors' explanation to the grand jurors of the "advice of counsel" defense was erroneous because the government instructed the grand jurors that advice of counsel was an affirmative defense to be raised at trial, explained JP Ellison of law firm Hyman, Phelps & McNamara.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze